China SXT Pharmaceuticals, Inc. (SXTC)
USD 2.28
(2.7%)
USD 2.28
(2.7%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -2.35 Million USD | 54.86% |
| 2023 | -5.2 Million USD | -10.01% |
| 2022 | -5.05 Million USD | -162.99% |
| 2021 | -1.85 Million USD | -140.11% |
| 2020 | -1 Million USD | 136.7% |
| 2019 | 1.95 Million USD | 10.95% |
| 2018 | 1.76 Million USD | 3.32% |
| 2017 | 1.7 Million USD | 470.75% |
| 2016 | 298.1 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 3.67 Million USD | 179.57% |
| 2024 Q1 | -4.62 Million USD | -133.05% |
| 2024 Q4 | 3.67 Million USD | 0.0% |
| 2024 FY | - USD | 64.74% |
| 2024 Q2 | -9.24 Million USD | 0.0% |
| 2023 Q2 | -1.04 Million USD | -100.0% |
| 2023 Q4 | -4.31 Million USD | -117.61% |
| 2023 Q3 | -1.98 Million USD | -90.66% |
| 2023 Q1 | -520.24 Thousand USD | -110.42% |
| 2023 FY | - USD | -10.01% |
| 2022 Q1 | -1.35 Million USD | -119.54% |
| 2022 Q4 | 4.99 Million USD | 561.58% |
| 2022 Q2 | -2.7 Million USD | -100.0% |
| 2022 Q3 | -1.08 Million USD | 60.01% |
| 2022 FY | - USD | -162.99% |
| 2021 Q3 | -1.59 Million USD | -342.95% |
| 2021 Q4 | 6.92 Million USD | 533.01% |
| 2021 FY | - USD | -140.11% |
| 2021 Q2 | 658.23 Thousand USD | -2.25% |
| 2021 Q1 | 673.36 Thousand USD | 104.97% |
| 2020 Q2 | -87.21 Thousand USD | -99.99% |
| 2020 Q3 | -461.03 Thousand USD | -428.65% |
| 2020 FY | - USD | 136.7% |
| 2020 Q1 | -43.6 Thousand USD | -102.44% |
| 2020 Q4 | -13.54 Million USD | -2836.9% |
| 2019 Q1 | 713.17 Thousand USD | 126.24% |
| 2019 FY | - USD | 10.95% |
| 2019 Q3 | 262.02 Thousand USD | -80.28% |
| 2019 Q2 | 1.32 Million USD | 86.34% |
| 2019 Q4 | 1.78 Million USD | 581.71% |
| 2018 FY | - USD | 3.32% |
| 2018 Q3 | 1.44 Million USD | 160.01% |
| 2018 Q4 | 315.23 Thousand USD | -78.13% |
| 2018 Q1 | 554.26 Thousand USD | 6.13% |
| 2018 Q2 | 554.26 Thousand USD | -0.0% |
| 2017 Q4 | 522.25 Thousand USD | 0.0% |
| 2017 FY | - USD | 470.75% |
| 2016 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | -150.1 Million USD | 98.434% |
| Theratechnologies Inc. | -10.31 Million USD | 77.203% |
| Safety Shot Inc | -12.18 Million USD | 80.706% |
| Cosmos Health Inc. | -17.06 Million USD | 86.221% |
| Cronos Group Inc. | -72.14 Million USD | 96.741% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 99.746% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 93.484% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 106.525% |
| Universe Pharmaceuticals INC | -3.21 Million USD | 26.875% |
| ProPhase Labs, Inc. | -14.82 Million USD | 84.144% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | 48.044% |
| Dynavax Technologies Corporation | 9.66 Million USD | 124.322% |
| Radius Health, Inc. | 38.31 Million USD | 106.137% |
| Alvotech | -484.86 Million USD | 99.515% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 38.526% |
| Alpha Teknova, Inc. | -25.53 Million USD | 90.794% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 98.52% |
| SCYNEXIS, Inc. | 73.47 Million USD | 103.2% |
| Harrow Health, Inc. | 9.72 Million USD | 124.18% |
| Biofrontera Inc. | -18.45 Million USD | 87.259% |
| DURECT Corporation | -24.68 Million USD | 90.476% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 102.393% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 102.151% |
| OptiNose, Inc. | -15.55 Million USD | 84.884% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 108.951% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | 298.901% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | -230.732% |
| SIGA Technologies, Inc. | 84.15 Million USD | 102.794% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | 389.533% |
| Shineco, Inc. | -26.55 Million USD | 91.146% |
| Phibro Animal Health Corporation | 84.6 Million USD | 102.779% |
| Procaps Group S.A. | 104.02 Million USD | 102.26% |
| TherapeuticsMD, Inc. | -8.4 Million USD | 72.015% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | 35.012% |
| Viatris Inc. | 3.51 Billion USD | 100.067% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 38.526% |
| Rockwell Medical, Inc. | -4.69 Million USD | 49.915% |
| Incannex Healthcare Limited | -18.5 Million USD | 87.295% |
| Aytu BioPharma, Inc. | -1.01 Million USD | -132.313% |
| Tilray Brands, Inc. | -72.84 Million USD | 96.772% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 100.763% |
| PetIQ, Inc. | 81.48 Million USD | 102.885% |
| Silver Spike Investment Corp. | 7.34 Million USD | 132.03% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 100.565% |
| Journey Medical Corporation | 1.92 Million USD | 222.385% |
| Alimera Sciences, Inc. | 7.27 Million USD | 132.312% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | 44.181% |
| Assertio Holdings, Inc. | -222.44 Million USD | 98.943% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | 41.087% |
| Embecta Corp. | 245.4 Million USD | 100.958% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 88.263% |
| Procaps Group, S.A. | 104.02 Million USD | 102.26% |
| PainReform Ltd. | -9.56 Million USD | 75.431% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 98.423% |
| Hempacco Co., Inc. | -12.77 Million USD | 81.594% |
| Talphera, Inc. | -9.84 Million USD | 76.112% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 101.443% |
| Alvotech | -484.86 Million USD | 99.515% |
| Lantheus Holdings, Inc. | 491 Million USD | 100.479% |
| Kamada Ltd. | 21.53 Million USD | 110.918% |
| Indivior PLC | 66 Million USD | 103.562% |
| Currenc Group, Inc. | -1.9 Million USD | -23.7% |
| Evoke Pharma, Inc. | -7.29 Million USD | 67.76% |
| Flora Growth Corp. | -45.87 Million USD | 94.875% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 88.263% |
| Evolus, Inc. | -41.81 Million USD | 94.377% |
| HUTCHMED (China) Limited | 25.52 Million USD | 109.21% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 100.974% |
| Akanda Corp. | -27.73 Million USD | 91.524% |